<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01552941</url>
  </required_header>
  <id_info>
    <org_study_id>SPM-005</org_study_id>
    <nct_id>NCT01552941</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Vagal Nerve Stimulation in Patients With Rheumatoid Arthritis</brief_title>
  <official_title>Pilot Study of the Safety and Efficacy of Neurostimulation of the Cholinergic Anti-Inflammatory Pathway Using an Active Implantable Vagal Nerve Stimulation Device in Patients With Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SetPoint Medical Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SetPoint Medical Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 12 week open label pilot study to determine the efficacy and safety of a surgically&#xD;
      implanted, electrically active vagal nerve stimulation device in patients with active&#xD;
      rheumatoid arthritis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in DAS from baseline</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with ACR 20 response</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Vagal Nerve Stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cyberonics VNS System</intervention_name>
    <description>Active Implantable Electrical Vagal Nerve Stimulator</description>
    <arm_group_label>Vagal Nerve Stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult-onset rheumatoid arthritis of at least six months duration as defined by the&#xD;
             2010 ACR/EULAR classification criteria (Aletaha, 2010)&#xD;
&#xD;
          -  Male or female patients, 18-75 years of age, inclusive&#xD;
&#xD;
          -  Functional status I, II, or III as classified according to the ACR 1991 revised&#xD;
             criteria (Hochberg, 1992)&#xD;
&#xD;
          -  Patients must have active disease as defined by at least 4 active tender or swollen&#xD;
             joints and CRP above 0.7 mg/dL, despite at least 3 months of treatment with&#xD;
             methotrexate at a dose of up to 25 mg orally per week.&#xD;
&#xD;
          -  Patients may have been previously treated with TNF antagonists, but must have failed&#xD;
             by reason of inadequate safety, intolerance to side effects, or development of&#xD;
             antibodies (i.e., secondary failures), and specifically cannot have failed on the&#xD;
             basis of primary lack of efficacy&#xD;
&#xD;
          -  Study amended to add a second cohort of up to 10 patients who have failed both a TNF&#xD;
             antagonist and at least one other biological therapy having a non-TNF antagonist&#xD;
             mechanism of action&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of unilateral or bilateral vagotomy&#xD;
&#xD;
          -  History of recurrent vaso-vagal syncope episodes&#xD;
&#xD;
          -  Known obstructive sleep apnea&#xD;
&#xD;
          -  Known history of cardiac rhythm disturbances, atrio-ventricular block of greater than&#xD;
             first degree, or cardiac conduction pathway abnormalities other than isolated right&#xD;
             bundle branch block or isolated left anterior fascicle block&#xD;
&#xD;
          -  Significant pharyngeal dysfunction or swallowing difficulties&#xD;
&#xD;
          -  Pre-existing clinically significant vocal cord damage or hoarseness&#xD;
&#xD;
          -  Previously implanted electrically active medical devices (e.g., cardiac pacemakers,&#xD;
             automatic implantable cardioverter-defibrillators)&#xD;
&#xD;
          -  Asthma or chronic obstructive pulmonary disease not controlled by medications, or any&#xD;
             other disease causing clinically significant dyspnea at time of screening&#xD;
&#xD;
          -  Active peptic ulcer disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul-Peter Tak, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sveučilišna klinička bolnica Mostar</name>
      <address>
        <city>Mostar</city>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinicki Centar Univerziteta, Reumatologija</name>
      <address>
        <city>Sarajevo</city>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sisters of Mercy Clinical Hospital Centre</name>
      <address>
        <city>Zagreb</city>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center, University of Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bosnia and Herzegovina</country>
    <country>Croatia</country>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Koopman FA, Chavan SS, Miljko S, Grazio S, Sokolovic S, Schuurman PR, Mehta AD, Levine YA, Faltys M, Zitnik R, Tracey KJ, Tak PP. Vagus nerve stimulation inhibits cytokine production and attenuates disease severity in rheumatoid arthritis. Proc Natl Acad Sci U S A. 2016 Jul 19;113(29):8284-9. doi: 10.1073/pnas.1605635113. Epub 2016 Jul 5.</citation>
    <PMID>27382171</PMID>
  </reference>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>March 8, 2012</study_first_submitted>
  <study_first_submitted_qc>March 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2012</study_first_posted>
  <last_update_submitted>October 28, 2016</last_update_submitted>
  <last_update_submitted_qc>October 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vagus Nerve</keyword>
  <keyword>Vagal Nerve Stimulation</keyword>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>Implantable Medical Device</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

